

Kawakami MD), **University of Tokyo, Tokyo, Japan** (Prof K Shibuya MD); University of California San Francisco, San Francisco, CA, USA (D S Kazi MD); **University of São Paulo, São Paulo, Brazil** (Prof A H Kemp PhD, Prof P A Lotufo DrPH); South African Medical Research Council, Cape Town, Western Cape, South Africa (A P Kengne PhD); Cardiology, Hadassah Ein Kerem University Hospital, Jerusalem, Israel (Prof A Keren MD); Jordan University of Science and Technology, Al-Ramtha, Jordan (Prof Y S Khader ScD); **Supreme Council of Health, Doha, Qatar** (S E A H Khalifa MSc); Health Services Academy, Islamabad, Punjab, Pakistan (E A Khan MPH); Institute of Health Policy and Management, Seoul National University College of Medicine, Seoul, South Korea (Prof Y Khang PhD); **University of Canberra, Canberra, ACT, Australia** (Y Kinfu PhD); Department of Infectious Disease Epidemiology, Division of Infectious Disease Control and Department of Health Statistics, Division of Epidemiology (R A White PhD), Norwegian Institute of Public Health, Oslo, Norway (J M Kinge PhD, Prof V Skirbekk PhD, Prof S E Vollset MD); Department of Preventive Cardiology, Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (Y Kokubo PhD); Center for Community Empowerment, Health Policy & Humanities, NIHRD, Jakarta, Indonesia (S Kosen MD); **University of Montreal, Montreal, QC, Canada** (Prof B Kuate Defo PhD); **Arkansas State University, Jonesboro, AR, USA** (V S Kulkarni PhD); Rajrajeshwari Medical College & Hospital, Bangalore, Karnataka, India (Prof C Kulkarni PhD); International Institute for Population Sciences, Mumbai, Maharashtra, India (K Kumar MPS); Indian Institute of Public Health, Public Health Foundation of India, Gurgaon, Haryana, India (R B Kumar MD); **Boston Medical Center, Boston, MA, USA** (G F Kwan MD); **Fourth View Consulting, Tallinn, Estonia** (T Lai PhD); Institute of Health Policy and Development Studies, National Institutes of Health, Manila, Philippines (Prof H Lam PhD); **National Cancer Institute, Rockville, MD, USA** (Q Lan PhD); **IAPB and Vision 2020 LA, Weston, FL, USA** (V C Lansingh PhD); London School of Hygiene and Tropical Medicine, Bloomsbury, UK (H J Larson PhD, Prof N Pearce PhD); **Korea University, Seoul, South Korea** (Prof J Lee PhD, Prof S Yoon PhD); University at Albany, The State University of New York, Rensselaer, NY, USA (R Leung PhD); National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (Y Li MPH, S Liu PhD, Prof L Wang MD, Prof M Zhou PhD); **Genentech, Inc, South San Francisco, CA, USA** (Y Li PhD); **Unidade Local de Saude de Matosinhos** (G M Lima BSc), **Northern Region Health Administration** (V M P Machado MSc), Public Health Department, Porto, Portugal; Wayne State University, Miami, FL, USA (S E Lipshultz MD); Centro Nacional para la Prevención y el Control del VIH/SIDA, Mexico City, Mexico (C Magis-Rodriguez PhD); Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia (M Majdan PhD); **University of Zambia, Lusaka, Zambia** (C C Mapoma PhD); **Queen Mary, University of London, London, UK** (Prof W Marcenés PhD); University of the East Ramon Magsaysay Medical Center, Quezon City, Philippines (M B Marzan MSc); Elmhurst Hospital Center, Mount Sinai Services, Elmhurst, NY, USA (Prof J R Masci MD);

Ministry of Public Health, Kabul, Afghanistan (M T Mashal PhD); **University of York, York, UK** (A J Mason-Jones PhD); Faculty of Health Sciences, Hatter Institute for Cardiovascular Research in Africa (Prof K Sliwa PhD), University of Cape Town, Cape Town, Western Cape, South Africa (Prof B M Mayosi DPhil); AIDC EC, Port Elizabeth, Eastern Cape, South Africa (T T Mazorodze MA); **EmergentCorp, Belize City, Belize** (A C Mckay PhD); **Pereleman School of Medicine** (P A Meaney MD), University of Pennsylvania, Philadelphia, PA, USA (Prof D H Silberberg MD); Janakpuri Superspecialty Hospital, New Delhi, India (Prof M M Mehndiratta MD); **Ministry of Health, Riyadh, Saudi Arabia** (Prof Z A Memish MD, M Y Saeedi PhD); **UNFPA, Lima, Peru** (W Mendoza MD); Pacific Institute for Research & Evaluation, Calverton MD, USA and Centre for Population Health Research, Curtin University, Perth, WA, Australia, (T R Miller PhD); **University of Ottawa, Ottawa, ON, Canada** (E J Mills PhD); **University of Salahaddin, Erbil, Iraq** (K A Mohammad PhD); University of Papua New Guinea, Port Moresby, NCD, Papua New Guinea (Prof G L Mola MD); Institute for Maternal and Child Health-IRCCS "Burlo Garofolo," Trieste, Italy (L Monasta DSc, M Montico Msc, L Ronfani PhD); **University of North Texas, Denton, TX, USA** (Prof A R Moore PhD); National Center for Child Health and Development, Setagaya, Tokyo, Japan (R Mori PhD); **Egerton University, Egerton, Rift Valley, Kenya** (W N Moturi PhD); Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan (M Mukaigawara MD); International Centre for Diarrhoeal Diseases Research, Dhaka, Bangladesh (A Naheed PhD); University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa (Prof K S Naidoo PhD); Azienda Ospedaliera papa Giovanni XXIII, Bergamo, Italy (Prof L Naldi MD); **Suraj Eye Institute, Nagpur, Maharashtra, India** (Prof V Nangia MD); School of Public Health, City University of New York, New York, NY, USA (Prof D Nash PhD); **Faculty of Medicine, Fez, Morocco** (Prof C Nejjarri PhD); National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA (R G Nelson PhD); Norwegian Center for Addiction Research (SERAF), University of Oslo, Oslo, Norway (S P Neupane MBBS); Kenya Medical Research Institute Wellcome Trust Programme, Kilifi, Kenya (Prof C R Newton MD); **Aga Khan University, Karachi, Pakistan** (M I Nisar MSc); **University of Bergen, Bergen, Norway** (Prof O F Norheim PhD, Prof S E Vollset); **Polytechnic of Namibia, Windhoek, Namibia** (V Nowaseb MSc); **Kyung Hee University, Seoul, Korea** (I Oh PhD); Teikyo University School of Medicine, Tokyo, Japan (Prof T Ohkubo MD); Center for Healthy Start Initiative, Ikoyi, Lagos, Nigeria (B O Olusanya PhD); Lira District Local Government, Lira Municipal Council, Northern Uganda, Uganda (J N Opiro MPH); Toxicology Unit, Faculty of Pharmacy, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria (Prof O E Orisakwe PhD); Christian Medical College Ludhiana, Ludhiana, India (Prof J D Pandian MD); **University of Calgary, Calgary, AB, Canada** (Prof S B Patten PhD); **AIIMS, New Delhi, India** (Prof V K Paul MD); **Independent, Waigani, NCD, Papua New Guinea** (B I Pavlin MD); 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine and ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal (Prof D M Pereira PhD); Postgraduate Medical Institute,

Lahore, Punjab, Pakistan (A Pervaiz MHA); **Flinders University, Adelaide, SA, Australia** (Prof K Pesudovs PhD); Centre for Applied Biostatistics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (Prof M Petzold PhD); University of British Columbia, Vancouver, BC, Canada (F Pourmalek PhD); College of Pharmacy, University of Illinois, Chicago, IL, USA (Prof D Qato PhD); **Contech Intl., Lahore, Punjab, Pakistan** (A Rafay MS); **Hamad Medical Corporation, Doha, Qatar** (S U Rahman FRCPC); **University of Missouri, Columbia, MO, USA** (M Raju PhD); Department of Public Health, University of the Punjab, Lahore, Punjab, Pakistan (S M Rana PhD); **Center for Disease Analysis, Louisville, CO, USA** (H Razavi PhD); **Private consultant, Cairns, QLD, Australia** (R Q Reilly MPH); IRCCS Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Bergamo, Italy (Prof G Remuzzi MD); Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Prof J H Richardus PhD); **BARC Hospital, Mumbai, Maharashtra, India** (Prof N Roy MD); **Rwanda Bio-Medical Center, Kigali, Rwanda** (N Sabin MD); National HIV/AIDS & STI Surveillance and Strategic Information Unit, National Epidemiology Center, Department of Health, Manila, National Capital Region, Philippines (G M J Samonte MD); **Marshall University, Huntington, WV, USA** (M Sawhney PhD); Federal University of Santa Catarina, Florianópolis, Brazil (I J C Schneider PhD); University of Alabama at Birmingham, Birmingham, AL, USA (Prof D C Schwebel PhD, J A Singh MD); Stellenbosch University, Cape Town, Western Cape, South Africa (Prof S Seedat PhD); **Health Canada, Ottawa, ON, Canada** (H H Shin PhD, S Weichenthal PhD); **Heriot-Watt University, Edinburgh, UK** (I Shiue PhD); **Center for Clinical Global Health Education** (R Shivakoti PhD), Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA (B X Tran PhD); **Reykjavik University, Reykjavik, Iceland** (Prof I D Sigfusdottir PhD); Instituto Nacional de Epidemiología Dr Juan H Jara, Mar del Plata, Buenos Aires, Argentina (A P Silva MgSc); Surveillance and Health Services Research Program American Cancer Society, Atlanta, GA, USA (E P Simard PhD); **Dartmouth College, Lebanon, NH, USA** (S Soneji PhD); Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation, Moscow, Russia (S S Soshnikov PhD); Faculty of Medicine and Health Sciences, University Tunku Abdul Rahman, Kajang, Selangor, Malaysia (C T Sreeramareddy MD); Centre Hospitalier Nord Deux-Sevres, Bressuire, France (V K Stathopoulou MD); KEELPNO (Centre for Disease Control, Greece, dispatched to "Alexandra" General Hospital of Athens), Athens, Greece (K Stroumpoulis PhD); National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India (S Swaminathan MD); Department of Criminology, Law and Society (and Sociology), University of California-Irvine, Chicago, IL, USA (B L Sykes PhD); **University of Illinois, Champaign, IL, USA** (K M Tabb PhD); Ministry of Health-MINSANTE, Yaounde, Centre, Cameroon (R T Talongwa MD); **Memorial University, St John's, NL, Canada** (E Y Tenkorang PhD); Department of Anesthesiology, University of Virginia, Charlottesville, VA, USA, and Department of Anesthesiology, King Fahad Medical City, Riyadh, Saudi Arabia (A S Terkawi MD); Adaptive Knowledge Management, Victoria, BC, Canada (A J Thomson PhD); The Earth Institute, Columbia University, New York, NY, USA

(A L Thorne-Lyman ScD); Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA (Prof J A Towbin MD); University of Southern Santa Catarina, Palhoça, Santa Catarina, Brazil (Prof J Traebert PhD); Department of Population Sciences and Development, Faculty of Economics and Management, University of Kinshasa, Kinshasa, Democratic Republic of the Congo (Z Tsala Dimbuene PhD); Department of Medicine, University of Crete, Heraklion, Greece (Prof M Tsimbaris PhD); Department of Veterans Affairs, Washington, DC, USA (U S Uchendu MD); Department of Internal Medicine, Federal Teaching Hospital Abakaliki, Abakailiki, Ebonyi State, Nigeria (K N Ukwaja MD); UKK Institute for Health Promotion Research, Tampere, Finland (Prof T J Vasankari PhD); Neuroscience Centre, Raffles Hospital, Singapore, Singapore (N Venketasubramanian MD); **University of Bologna, Bologna, Italy** (Prof F S Violante MD); **Higher School of Economics, Moscow, Russia** (Prof V V Vlassov MD); Uniformed Services University of Health Sciences, Bethesda, MD, USA (S Waller MD); VA Medical Center and Georgetown University Neurology Department, Washington, DC, USA (M T Wallin MD); Shandong University Affiliated Jinan Central Hospital, Jinan, China (X R Wang PhD); National Office for Maternal and Child Health Surveillance, Chengdu, China (Prof Y Wang BS, Prof J Zhu MD); **University of Marburg, Marburg, Germany** (R Westerman PhD); **University of Miami, Miami, FL, USA** (J D Wilkinson MD); Institute of Public Health, University of Gondar, Gondar, Ethiopia (S M Woldeyohannes MPH); Ateneo School of Medicine and Public Health, Pasig City, Metro Manila, Philippines (J Q Wong MD); Nanjing University School of Medicine, Jinling Hospital, Nanjing, China (Prof G Xu PhD); University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (Y C Yang PhD); Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan (Y Yano MD); The University of Hong Kong, Hong Kong, Hong Kong (Prof P Yip PhD); National Center of Neurology and Psychiatry, Kodira, Tokyo, Japan (N Yonemoto MPH); **Jackson State University, Jackson, MS, USA** (Prof M Younis PhD); Department of Epidemiology and Biostatistics, School of Public Health and Global Health Institute, Wuhan University, Wuhan, China (Prof C Yu PhD); TCM MEDICAL TK SDN BHD, Nusajaya, Johor Bahru, Malaysia (K Yun Jin PhD); **Mansoura Faculty of Medicine, Mansoura, Egypt** (Prof M E S Zaki MD); **Chongqing Medical University, Chongqing, China** (Prof Y Zhao MD); Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China (Y Zheng PhD); Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China (Prof X N Zou MD)

Affiliations

Institute for Health Metrics and Evaluation (Prof C J L Murray DPhil, K F Ortblad MPH, C Guinovart PhD, S S Lim PhD, T M Wolock BA, D A Roberts BS, E A Dansereau BA, N Graetz BS, R M Barber BS, J C Brown MAIS, H Wang PhD, H C Duber MD, M Naghavi PhD, D Dicker BS, Prof L Dandona MD, K R Heuton BS, D E Phillips BS, T D Fleming BS, A D Flaxman PhD, B K Phillips BA, E K Johnson BA, M S Coggeshall BA, M H Forouzanfar MD, Prof A H Mokdad PhD, M Ng PhD, Prof T Vos PhD), Harborview and University of Washington Medicine, Seattle, WA, USA

(Prof R G Ellenbogen MD), **University of Washington, Seattle, WA, USA** (R Alfonso-Cristancho PhD, Prof B O Anderson MD, P N Jensen MPH, D A Quistberg PhD); Public Health Foundation of India, New Delhi, India (Prof L Dandona, R Dandona PhD, G A Kumar PhD, K S Murthy MPH); **Imperial College London, London, UK** (K Foreman MPH, Prof T N Williams MD); **Harvard School of Public Health (E L Ding ScD), Harvard University, Cambridge, MA, USA** (Prof J A Salomon PhD); Faculty of Medicine, Cairo-University, Cairo, Egypt (Prof F Abd-Allah MD); College of Health Sciences, School of Public Health (S F Abera MSc), **Mekelle University, Mekelle, Ethiopia** (Y A Melaku MPH); University of Texas School of Medicine San Antonio, San Antonio, TX, USA (J P Abraham MD); **University College London, London, UK** (Prof I Abubakar PhD); Weill Cornell Medical College in Qatar, Doha, Qatar (L J Abu-Raddad PhD); Institute of Community and Public Health-Birzeti University, Ramallah, West Bank, Occupied Palestinian Territory (N M Abu-Rmeileh PhD); **Ministry of Health, Gaborone, Botswana** (T Achoki MD); Evidence For Action (MamaYe), Freetown, Western Area, Sierra Leone (A O Adeyemo MHM); Association Ivoirienne Pour Le Bien Etre Familial, Abidjan, Côte d'Ivoire (A K Adou MD); **University of Extremadura, Cáceres, Spain** (Prof J C Adsuar PhD, U Fra.Paleo PhD); Institution of Public Health Sciences, Stockholm, Sweden (E E Agardh PhD); **Makerere University, Kampala, Uganda** (D Akena PhD, L Nyakarahuka MPH); **Ministry of Health, Muscat, Oman** (M J Al Kahbouri PhD, D Alasfoor MSc); **Independent, Damascus, Syria** (M I Albittar MSc); Grupo de Investigación en Ciencias de la Salud y Neurociencias (CISNEURO), Cartagena de Indias, Colombia (G Alcalá-Cerra MD); Facultad de Medicina, Departamento de Medicina Preventiva y Social, Universidad de la República, Montevideo, Uruguay (M A Alegretti MD); **Debre Markos University, Debre Markos, Ethiopia** (Z A Alemu MPH); National Guard Health Affairs, Riyadh, Saudi Arabia (S Alhabib PhD); **University of Oxford, Oxford, UK** (R Ali MSc, Prof S I Hay DPhil, K Rahimi DM); School of Public Health, University of Lorraine, Nancy, France (Prof F Alla PhD); **Ministry of Health, Belmopan, Cayo, Belize** (P J Allen MPH); Charité Universitätsmedizin Berlin, Berlin, Germany (U Alsharif DMD, S Nolte PhD, C Papachristou PhD); **Government, Madrid, Spain** (E Alvarez PhD); Universidad de Cartagena, Cartagena de Indias, Colombia (Prof N Alvis-Guzman PhD, A J Paternina Caicedo MSc); **Albany State University, Albany, GA, USA** (Prof A A Amankwaa PhD); Department of Epidemiology, University of Groningen, Groningen, The Netherlands and College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia (A T Amare MPH); Kurdistan Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Kurdistan, Iran (H Amini MSPH); **Ministry of Public Health, Beirut, Lebanon**(Prof W Ammar PhD, H L Harb MPH); College of Public Health, University of the Philippines Manila, Manila, Philippines (C A T Antonio MD, E J A Faraon MD); **UNFPA, Kabul, Afghanistan** (P Anwari MSc); **Uppsala University, Uppsala, Sweden** (J Ärnlov PhD, Prof A Larsson PhD); **Malaria & Other Parasitic Diseases Division** (C K Karema MSc), **Ministry of Health, Kigali, Rwanda** (A Binagwaho MMed [Ped], I Kankindi MSc); Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia (Prof V S Arsic

Arsenijevic PhD); **Median Inc, Windsor, ON, Canada** (A Artaman PhD); South Asian Public Health Forum, Islamabad, Pakistan (R J Asghar MD); Mashhad University of Medical Sciences, Mashhad, Iran (R Assadi PhD); Ministry of Health, Wellness, Human Services and Gender Relations, Castries, St. Lucia (L S Atkins MPH); Public Health Agency of Canada, Toronto, ON, Canada (A Badawi PhD); **Sri Ramachandra University, Chennai, India** (Prof K Balakrishnan PhD); **University of Birmingham, Birmingham, UK** (A Banerjee DPhil); **Stanford University School of Medicine** (L Gaffikin DrPH), **Stanford University** (S Basu PhD), Stanford, CA, USA; Oxford University, Ho Chi Minh City, Vietnam (J Beardsley MBChB); **Madawalabu University, Bale Goba, Ethiopia** (T Bekele MPH); **Yale University, New Haven, CT, USA** (Prof M L Bell PhD, J J Huang MD); **King's College London, London, UK** (E Bernabe PhD); **Addis Ababa University, Addis Ababa, Ethiopia** (T J Beyene MSC, K Deribe MPH); **Wellington Hospital, Wellington, New Zealand** (N Bhala DPhil); Postgraduate Institute of Medical Education and Research, Chandigarh, India (A Bhalla MD, Prof V Jha DM); Aga Khan University Medical Center, Nairobi, Kenya (Prof Z A Bhutta PhD); University of Missouri-Kansas City, Kansas City, MO, USA (A Bin Abdulhak MD); General Practice and Primary Health Care Academic Centre (P P Chiang PhD), University of Melbourne, Melbourne, VIC, Australia (J D Blore PhD, A Lakshmana Balaji MBBS, Prof A D Lopez PhD, R G Weintraub MB); Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia (R G Weintraub); **General Directorate of Health Research** (B Bora Basara PhD, G K Yentur PhD), **Ministry of Health, Ankara, Turkey** (Prof U Dilmen MD, S B Uzan MD); **World Bank, Washington, DC, USA** (D Bose PhD); **Danube-University Krems, Krems, Austria** (Prof M Brainin PhD); **University of Arizona, Tucson, AZ, USA** (Prof N Breitborde PhD); Colombian National Health Observatory, Instituto Nacional de Salud, Bogota, Colombia (C A Castañeda-Orjuela MSc); Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Ministry of Health, Madrid, Spain (F Catalá-López PhD); National Tuberculosis Institute, Bangalore, India (V K Chadha MD); Institute of Epidemiology and Preventive Medicine (H Lin ScD), **National Taiwan University, Taipei, Taiwan** (Prof J Chang PhD); Department of Parasitology, College of Medicine, Taipei Medical University, Taipei, Taiwan and Center for International Tropical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (Prof T Chuang PhD); **UNICEM, Montevideo, Uruguay** (M Colomar MSc); **Mayo Clinic, Rochester, MN, USA** (Prof L T Cooper MD); MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK (Prof C Cooper FMedSci); Hospital Dr. Gustavo N. Collado, Chitre, Herrera, Panama (K J Courville MD); Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia (B C Cowie PhD, J H Maclachlan MSc); University of California, San Diego, La Jolla, CA, USA (Prof M H Criqui MD); **Emory University School of Medicine** (A Dayama MD), **Emory University, Atlanta, GA, USA** (Prof Y Liu PhD, Prof K M V Narayan MD, S B Omer PhD); **Griffith University, Brisbane, QLD, Australia** (Prof D De Leo DSc); **The Kirby Institute** (A J Vallely PhD), University of New South Wales, Sydney, NSW, Australia (Prof L Degenhardt PhD); **University of**

Auckland, Auckland, New Zealand (B Del Pozo-Cruz PhD); **Beth Israel Medical Center, New York, NY, USA** (Prof D C Des Jarlais PhD); Africa Medical and Research Foundation in Ethiopia, Addis Ababa, Ethiopia (M Dessalegn MPH); **University of Peradeniya, Peradeniya, Sri Lanka** (S D Dharmaratne MD); **Sydney School of Public Health** (T R Driscoll PhD), **University of Sydney, Sydney, NSW, Australia** (J Leigh PhD); National Institutes of Health, Montgomery Village, MD, USA (A M Durrani MD); The Institute of Social and Economic Studies of Population at the Russian Academy of Sciences, Moscow, Russia (Prof S P Ermakov DSc); **Non-Communicable Diseases Research Center** (F Farzadfar MD), **Endocrinology and Metabolism Research Center** (Prof A Esteghamati MD, N Hafezi-Nejad MD, S Sheikhabahaei MD), **Sina Trauma and Surgery Research Center** (Prof V Rahimi-Movaghar MD), **MS Research Center** (M A Sahraian MD), **Digestive Diseases Research Institute** (S G Sepanlou MD), Tehran University of Medical Sciences, Tehran, Iran; Department of Neurobiology, Care Sciences and Society (NVS) (S Fereshtehnejad MD), Department of Medical Epidemiology and Biostatistics (Prof E Weiderpass PhD), **Karolinska Institutet, Stockholm, Sweden** (R Havmoeller PhD); **Heller Graduate School**, (D O Fijabi MBBS), **Heller School for Social Policy and Management** (E L Glaser MSc), **Brandeis University, Waltham, MA, USA** (B T Idrisov MD); National Centre for Disease Control and Public Health, Tbilisi, Georgia (A Gamkrelidze PhD, M Kereselidze PhD, I Khonelidze MPA); Clinique Coopérative de Parakou, Parakou, Borgou, Benin (F G Gankpé MD); Division of Human Nutrition, Wageningen University, Wageningen, Netherlands (J M Geleijnse PhD); **Agence de Medecine Preventive, Paris, France** (B D Gessner MD); **Eastern Health Clinical School** (B K Lloyd PhD), **Monash University, Melbourne, VIC, Australia** (K B Gibney MBBS); Turning Point, Eastern Health, Fitzroy, VIC, Australia (B K Lloyd); College of Medicine, University of Hail, Hail, Saudi Arabia (I A M Ginawi MD); University of Massachusetts Medical School, Worcester, MA, USA (Prof P Gona PhD); Department of Diabetes Research, National Center for Global Health and Medicine, Tokyo, Japan (A Goto PhD); **School of Population Health** (D G Hoy PhD), University of Queensland, Brisbane, QLD, Australia (H N Gouda PhD, L Knibbs PhD); Public Health Division, Secretariat of the Pacific Community, Noumea, New Caledonia (D G Hoy); Saint James School of Medicine, Kralendijk, Bonaire, Netherlands Antilles (Prof H C Gugnani PhD); **Fortis Escorts Hospital, Jaipur, India** (R Gupta PhD); Kanawha Charleston Health Department, Charleston, WV, USA (R Gupta MD); **Arabian Gulf University, Manama, Bahrain** (Prof R R Hamadeh DPhil); Wayne County Department of Health and Human Services, Detroit, MI, USA (M Hammami MD); School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia (Prof G J Hankey MD); Parc Sanitari Sant Joan de Déu, CIBERSAM, University of Barcelona, Sant Boi de Llobregat, Barcelona, Spain (Prof J M Haro MD); Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran (Prof M T Hedayati PhD); National Institute of Public Health of Mexico, Cuernavaca, Morelos, Mexico (I B Heredia Pi PhD, F Mejia-Rodriguez MD, A D Quezada MSc, Prof E E Servan-Mori MSc); Parnassia Psychiatric Institute, The Hague, Netherlands (Prof H W Hoek MD); **Cedar**

Associates, Menlo Park, CA, USA (Prof J C Hornberger MD); Albert Einstein College of Medicine, Bronx, NY, USA (Prof H D Hosgood PhD); **Baylor College of Medicine, Houston, TX, USA** (Prof P J Hotez PhD); **Aarhus University, Aarhus, Denmark** (K M Iburg PhD); National Institute for Health Development, Tallinn, Estonia (K Innos PhD, M Leinsalu PhD); **George Mason University, Fairfax, VA, USA** (K H Jacobsen PhD); Centre for Chronic Disease Control, New Delhi, India (P Jeemon PhD); Tianjin Centers for Diseases Control and Prevention, Tianjin, China (Prof G Jiang MD); Department of Ophthalmology, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany (Prof J B Jonas MD); The National Institute of Public Health, Copenhagen, Denmark (Prof K Juel PhD); **Fudan University, Shanghai, China** (Prof H Kan MD); **University of Balamand, Beirut, Lebanon** (Prof N E Karam MD); Helmholtz Centre for Infection Research, Braunschweig, Germany and German Center for Infection Research (DZIF), Hannover-Braunschweig site, Germany (A Karch MD); **Oklahoma State University, Tulsa, OK, USA** (A Kaul MD); **School of Public Health** (Prof N Kawakami MD), **University of Tokyo, Tokyo, Japan** (Prof K Shibuya MD); University of California San Francisco, San Francisco, CA, USA (D S Kazi MD); **University of São Paulo, São Paulo, Brazil** (Prof A H Kemp PhD, Prof P A Lotufo DrPH); South African Medical Research Council, Cape Town, Western Cape, South Africa (A P Kengne PhD); Cardiology, Hadassah Ein Kerem University Hospital, Jerusalem, Israel (Prof A Keren MD); Jordan University of Science and Technology, Al-Ramtha, Jordan (Prof Y S Khader ScD); **Supreme Council of Health, Doha, Qatar** (S E A H Khalifa MSc); Health Services Academy, Islamabad, Punjab, Pakistan (E A Khan MPH); Institute of Health Policy and Management, Seoul National University College of Medicine, Seoul, South Korea (Prof Y Khang PhD); **University of Canberra, Canberra, ACT, Australia** (Y Kinfu PhD); Department of Infectious Disease Epidemiology, Division of Infectious Disease Control and Department of Health Statistics, Division of Epidemiology (R A White PhD), Norwegian Institute of Public Health, Oslo, Norway (J M Kinge PhD, Prof V Skirbekk PhD, Prof S E Vollset MD); Department of Preventive Cardiology, Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (Y Kokubo PhD); Center for Community Empowerment, Health Policy & Humanities, NIHRD, Jakarta, Indonesia (S Kosen MD); **University of Montreal, Montreal, QC, Canada** (Prof B Kuate Defo PhD); **Arkansas State University, Jonesboro, AR, USA** (V S Kulkarni PhD); Rajrajeshwari Medical College & Hospital, Bangalore, Karnataka, India (Prof C Kulkarni PhD); International Institute for Population Sciences, Mumbai, Maharashtra, India (K Kumar MPS); Indian Institute of Public Health, Public Health Foundation of India, Gurgaon, Haryana, India (R B Kumar MD); **Boston Medical Center, Boston, MA, USA** (G F Kwan MD); **Fourth View Consulting, Tallinn, Estonia** (T Lai PhD); Institute of Health Policy and Development Studies, National Institutes of Health, Manila, Philippines (Prof H Lam PhD); **National Cancer Institute, Rockville, MD, USA** (Q Lan PhD); **IAPB and Vision 2020 LA, Weston, FL, USA** (V C Lansingh PhD); London School of Hygiene and Tropical Medicine, Bloomsbury, UK (H J Larson PhD, Prof N Pearce PhD); **Korea University, Seoul,**

South Korea (Prof J Lee PhD, Prof S Yoon PhD); University at Albany, The State University of New York, Rensselaer, NY, USA (R Leung PhD); National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China (Y Li MPH, S Liu PhD, Prof L Wang MD, Prof M Zhou PhD); **Genentech, Inc, South San Francisco, CA, USA** (Y Li PhD); **Unidade Local de Saude de Matosinhos (G M Lima BSc), Northern Region Health Administration (V M P Machado MSc), Public Health Department, Porto, Portugal**; Wayne State University, Miami, FL, USA (S E Lipshultz MD); Centro Nacional para la Prevención y el Control del VIH/SIDA, Mexico City, Mexico (C Magis-Rodriguez PhD); Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia (M Majdan PhD); **University of Zambia, Lusaka, Zambia (C C Mapoma PhD)**; **Queen Mary, University of London, London, UK** (Prof W Marcenés PhD); University of the East Ramon Magsaysay Medical Center, Quezon City, Philippines (M B Marzan MSc); Elmhurst Hospital Center, Mount Sinai Services, Elmhurst, NY, USA (Prof J R Masci MD); **Ministry of Public Health, Kabul, Afghanistan (M T Mashal PhD)**; **University of York, York, UK** (A J Mason-Jones PhD); Faculty of Health Sciences, Hatter Institute for Cardiovascular Research in Africa (Prof K Sliwa PhD), University of Cape Town, Cape Town, Western Cape, South Africa (Prof B M Mayosi DPhil); AIDC EC, Port Elizabeth, Eastern Cape, South Africa (T T Mazorodze MA); **EmergentCorp, Belize City, Belize (A C McKay PhD)**; **Pereleman School of Medicine (P A Meaney MD), University of Pennsylvania, Philadelphia, PA, USA (Prof D H Silberberg MD)**; Janakpuri Superspecialty Hospital, New Delhi, India (Prof M M Mehndiratta MD); **Ministry of Health, Riyadh, Saudi Arabia (Prof Z A Memish MD, M Y Saeedi PhD)**; **UNFPA, Lima, Peru (W Mendoza MD)**; Pacific Institute for Research & Evaluation, Calverton MD, USA and Centre for Population Health Research, Curtin University, Perth, WA, Australia, (T R Miller PhD); **University of Ottawa, Ottawa, ON, Canada (E J Mills PhD)**; **University of Salahaddin, Erbil, Iraq (K A Mohammad PhD)**; University of Papua New Guinea, Port Moresby, NCD, Papua New Guinea (Prof G L Mola MD); Institute for Maternal and Child Health-IRCCS "Burlo Garofolo," Trieste, Italy (L Monasta DSc, M Montico Msc, L Ronfani PhD); **University of North Texas, Denton, TX, USA (Prof A R Moore PhD)**; National Center for Child Health and Development, Setagaya, Tokyo, Japan (R Mori PhD); **Egerton University, Egerton, Rift Valley, Kenya (W N Moturi PhD)**; Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan (M Mukaigawara MD); International Centre for Diarrhoeal Diseases Research, Dhaka, Bangladesh (A Naheed PhD); University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa (Prof K S Naidoo PhD); Azienda Ospedaliera papa Giovanni XXIII, Bergamo, Italy (Prof L Naldi MD); **Suraj Eye Institute, Nagpur, Maharashtra, India (Prof V Nangia MD)**; School of Public Health, City University of New York, New York, NY, USA (Prof D Nash PhD); **Faculty of Medicine, Fez, Morocco (Prof C Nejari PhD)**; National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA (R G Nelson PhD); Norwegian Center for Addiction Research (SERAF), University of Oslo, Oslo, Norway (S P Neupane MBBS); Kenya Medical Research Institute Wellcome Trust Programme, Kilifi, Kenya (Prof C R Newton MD);

Aga Khan University, Karachi, Pakistan (M I Nisar MSc); **University of Bergen, Bergen, Norway** (Prof O F Norheim PhD, Prof S E Vollset); **Polytechnic of Namibia, Windhoek, Namibia** (V Nowaseb MSc); **Kyung Hee University, Seoul, Korea** (I Oh PhD); Teikyo University School of Medicine, Tokyo, Japan (Prof T Ohkubo MD); Center for Healthy Start Initiative, Ikoyi, Lagos, Nigeria (B O Olusanya PhD); Lira District Local Government, Lira Municipal Council, Northern Uganda, Uganda (J N Opió MPH); Toxicology Unit, Faculty of Pharmacy, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria (Prof O E Orisakwe PhD); Christian Medical College Ludhiana, Ludhiana, India (Prof J D Pandian MD); **University of Calgary, Calgary, AB, Canada** (Prof S B Patten PhD); **AIIMS, New Delhi, India** (Prof V K Paul MD); **Independent, Waigani, NCD, Papua New Guinea** (B I Pavlin MD); 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine and ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal (Prof D M Pereira PhD); Postgraduate Medical Institute, Lahore, Punjab, Pakistan (A Pervaiz MHA); **Flinders University, Adelaide, SA, Australia** (Prof K Pesudovs PhD); Centre for Applied Biostatistics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (Prof M Petzold PhD); University of British Columbia, Vancouver, BC, Canada (F Pourmalek PhD); College of Pharmacy, University of Illinois, Chicago, IL, USA (Prof D Qato PhD); **Contech Intl., Lahore, Punjab, Pakistan** (A Rafay MS); **Hamad Medical Corporation, Doha, Qatar** (S U Rahman FRCPCH); **University of Missouri, Columbia, MO, USA** (M Raju PhD); Department of Public Health, University of the Punjab, Lahore, Punjab, Pakistan (S M Rana PhD); **Center for Disease Analysis, Louisville, CO, USA** (H Razavi PhD); **Private consultant, Cairns, QLD, Australia** (R Q Reilly MPH); IRCCS Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Bergamo, Italy (Prof G Remuzzi MD); Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Prof J H Richardus PhD); **BARC Hospital, Mumbai, Maharashtra, India** (Prof N Roy MD); **Rwanda Bio-Medical Center, Kigali, Rwanda** (N Sabin MD); National HIV/AIDS & STI Surveillance and Strategic Information Unit, National Epidemiology Center, Department of Health, Manila, National Capital Region, Philippines (G M J Samonte MD); **Marshall University, Huntington, WV, USA** (M Sawhney PhD); Federal University of Santa Catarina, Florianópolis, Brazil (I J C Schneider PhD); University of Alabama at Birmingham, Birmingham, AL, USA (Prof D C Schwebel PhD, J A Singh MD); Stellenbosch University, Cape Town, Western Cape, South Africa (Prof S Seedat PhD); **Health Canada, Ottawa, ON, Canada** (H H Shin PhD, S Weichenthal PhD); **Heriot-Watt University, Edinburgh, UK** (I Shiue PhD); **Center for Clinical Global Health Education** (R Shivakoti PhD), Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA (B X Tran PhD); **Reykjavik University, Reykjavik, Iceland** (Prof I D Sigfusdottir PhD); Instituto Nacional de Epidemiología Dr Juan H Jara, Mar del Plata, Buenos Aires, Argentina (A P Silva MgSc); Surveillance and Health Services Research Program American Cancer Society, Atlanta, GA, USA (E P Simard PhD); **Dartmouth College, Lebanon, NH, USA** (S Soneji PhD); Federal Research Institute for Health Organization and

Informatics of Ministry of Health of the Russian Federation, Moscow, Russia (S S Soshnikov PhD); Faculty of Medicine and Health Sciences, University Tunku Abdul Rahman, Kajang, Selangor, Malaysia (C T Sreeramareddy MD); Centre Hospitalier Nord Deux-Sevres, Bressuire, France (V K Stathopoulou MD); KEELPNO (Centre for Disease Control, Greece, dispatched to "Alexandra" General Hospital of Athens), Athens, Greece (K Stroumpoulis PhD); National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India (S Swaminathan MD); Department of Criminology, Law and Society (and Sociology), University of California-Irvine, Chicago, IL, USA (B L Sykes PhD); **University of Illinois, Champaign, IL, USA** (K M Tabb PhD); Ministry of Health-MINSANTE, Yaounde, Centre, Cameroon (R T Talongwa MD); **Memorial University, St John's, NL, Canada** (E Y Tenkorang PhD); Department of Anesthesiology, University of Virginia, Charlottesville, VA, USA, and Department of Anesthesiology, King Fahad Medical City, Riyadh, Saudi Arabia (A S Terkawi MD); Adaptive Knowledge Management, Victoria, BC, Canada (A J Thomson PhD); The Earth Institute, Columbia University, New York, NY, USA (A L Thorne-Lyman ScD); Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA (Prof J A Towbin MD); University of Southern Santa Catarina, Palhoça, Santa Catarina, Brazil (Prof J Traebert PhD); Department of Population Sciences and Development, Faculty of Economics and Management, University of Kinshasa, Kinshasa, Democratic Republic of the Congo (Z Tsala Dimbuene PhD); Department of Medicine, University of Crete, Heraklion, Greece (Prof M Tsilimbaris PhD); Department of Veterans Affairs, Washington, DC, USA (U S Uchendu MD); Department of Internal Medicine, Federal Teaching Hospital Abakaliki, Abakailiki, Ebonyi State, Nigeria (K N Ukwaja MD); UKK Institute for Health Promotion Research, Tampere, Finland (Prof T J Vasankari PhD); Neuroscience Centre, Raffles Hospital, Singapore, Singapore (N Venketasubramanian MD); **University of Bologna, Bologna, Italy** (Prof F S Violante MD); **Higher School of Economics, Moscow, Russia** (Prof V V Vlassov MD); Uniformed Services University of Health Sciences, Bethesda, MD, USA (S Waller MD); VA Medical Center and Georgetown University Neurology Department, Washington, DC, USA (M T Wallin MD); Shandong University Affiliated Jinan Central Hospital, Jinan, China (X R Wang PhD); National Office for Maternal and Child Health Surveillance, Chengdu, China (Prof Y Wang BS, Prof J Zhu MD); **University of Marburg, Marburg, Germany** (R Westerman PhD); **University of Miami, Miami, FL, USA** (J D Wilkinson MD); Institute of Public Health, University of Gondar, Gondar, Ethiopia (S M Woldeyohannes MPH); Ateneo School of Medicine and Public Health, Pasig City, Metro Manila, Philippines (J Q Wong MD); Nanjing University School of Medicine, Jinling Hospital, Nanjing, China (Prof G Xu PhD); University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (Y C Yang PhD); Division of Cardiovascular Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan (Y Yano MD); The University of Hong Kong, Hong Kong, Hong Kong (Prof P Yip PhD); National Center of Neurology and Psychiatry, Kodira, Tokyo, Japan (N Yonemoto MPH); **Jackson State University, Jackson, MS, USA** (Prof M Younis PhD); Department of Epidemiology and Biostatistics, School of Public Health and Global Health Institute, Wuhan University, Wuhan, China (Prof C Yu PhD); TCM

MEDICAL TK SDN BHD, Nusajaya, Johor Bahru, Malaysia (K Yun Jin PhD);
Mansoura Faculty of Medicine, Mansoura, Egypt (Prof M E S Zaki MD);
Chongqing Medical University, Chongqing, China (Prof Y Zhao MD); Zhongshan
 Ophthalmic Center, Sun Yat-sen University, Guangzhou, China (Y Zheng PhD);
 Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China
 (Prof X N Zou MD)

Acknowledgments

We thank the countless individuals who have contributed to the Global Burden of Disease Study 2013 in various capacities. We would like to acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: Michael F MacIntyre, Peter Speyer, and Summer Lockett Ohno for their management of the Global Burden of Disease Study 2013; Kelsey Pierce for her valuable assistance; Peter Speyer, James Bullard, Serkan Yalcin, Edgar Sioson, Evan Laurie, Charles Atkinson, and Andrew Ernst for their tireless support of the computational infrastructure necessary to produce the results; Linda A Ettinger for her expert administrative support; Peter Speyer, Abigail McLain, James Hancock, Marissa Iannarone, and Eden Stork for their persistent and invaluable work to gain access to and catalogue as much data as possible to inform the estimates; Stan Biryukov for his assistance with the tuberculosis database; Henry Apfel and Madeline Moyer for data extraction and processing; Christopher Margono, Michelle Subart, Lavanya Singh and Margaret Lind for assistance with galleys; Matthew M Coates, Carly E Levitz, Chelsea A Lidell, Meghan D Mooney, and Austin E Schumaker for production of all-cause mortality estimates; Amelia Bertozzi-Villa for review of Python coding of the Spectrum model. We would also like to acknowledge Mary Mahy, Keith Sabin and John Stover for sharing the UNAIDS EPP files with us and especially John Stover for responding to multiple queries regarding Spectrum. Additionally, Ibrahim Abubakar would like to acknowledge the UK National Institute for Health Research and MRC for funding. Laith J Abu-Raddad would like to acknowledge the support of Qatar National Research Fund (NPRP 04-924-3-251) who provided the main funding for generating the data provided to the GBD-IHME effort. Gabriel Alcalá-Cerra would like to acknowledge institutional support from Health Sciences and Neurosciences (CISNEURO) Research Group. Louisa Degenhardt is supported by an Australian National Health and Medical Research Council Principal Research Fellowship (#1041742). Dr. Des Jarlais would like to acknowledge funding from NIH Grant DA R01 003574. KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine [grant number 099876]. Prof. Giuseppe Remuzzi would like to acknowledge the International Society of Nephrology (ISN) for their support of his involvement in the GBD 2013. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. Dr. Soneji was supported by the National Center for Advancing Translational Sciences grant number KL2TR001088. Karen M Tabb would like to acknowledge her current support: Lemann Institute Faculty Research Grant, University of Illinois. Andrew J Valley is supported by a Training Fellowship from the National Health and Medical Research Council (NHMRC), Australia. Gelin Xu is currently funded by the Nature Science Foundation of China (NSFC, 81070922). No individuals acknowledged received additional compensation for their efforts.

References

1. Institute for Health Metrics and Evaluation. Financing Global Health 2013: Transition in an Age of Austerity. IHME; Seattle, WA: 2013.
2. Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002-11, and requirements to meet 2015 targets. *Lancet Glob Health*. 2013; 1:e105-15. [PubMed: 25104145]
3. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. *Lancet*. 2002; 359:1635-43. [PubMed: 12020523]
4. Vassall A, Remme M. Financing tuberculosis control: promising trends and remaining challenges. *Lancet Glob Health*. 2013; 1:e62-63. [PubMed: 25104150]
5. Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. *Lancet*. 2010; 376:1254-60. [PubMed: 20934597]

6. Snow RW, Guerra CA, Mutheu JJ, Hay SI. International funding for malaria control in relation to populations at risk of stable *Plasmodium falciparum* transmission. *PLoS Med.* 2008; 5:e142. [PubMed: 18651785]
7. Snow RW, Okiro EA, Gething PW, Atun R, Hay SI. Equity and adequacy of international donor assistance for global malaria control: an analysis of populations at risk and external funding commitments. *Lancet.* 2010; 376:1409–16. [PubMed: 20889199]
8. Korenromp EL, Hosseini M, Newman RD, Cibulskis RE. Progress towards malaria control targets in relation to national malaria programme funding. *Malar J.* 2013; 12:18. [PubMed: 23317000]
9. Waddington, C.; Martin, J.; Walford, V. Trends in International Funding for Malaria Control. HLSP Institute; London, UK: 2005. http://rbm.who.int/docs/hlsp_report.pdf [accessed February 26, 2014]
10. Waage J, Banerji R, Campbell O, et al. The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015 *Lancet* and London International Development Centre Commission. *Lancet.* 2010; 376:991–1023. [PubMed: 20833426]
11. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annu Rev Public Health.* 2013; 34:271–86. [PubMed: 23244049]
12. United Nations. The Millennium Development Goals Report 2013. United Nations; New York, NY: 2013. <http://www.un.org/millenniumgoals/pdf/report-2013/mdg-report-2013-english.pdf> [accessed February 26, 2014]
13. Clemens MA, Kenny CJ, Moss TJ. The Trouble with the MDGs: Confronting Expectations of Aid and Development Success. *World Dev.* 2007; 35:735–51.
14. Atun R, Raviglione M, Marais B, Zumla A. Tuberculosis control is crucial to achieve the MDGs. *Lancet.* 2010; 376:940–41. [PubMed: 20851247]
15. Lomazzi M, Borisch B, Laaser U. The Millennium Development Goals: experiences, achievements and what's next. *Glob Health Action.* 2014; 7:23695. [PubMed: 24560268]
16. Fehling M, Nelson BD, Venkatapuram S. Limitations of the Millennium Development Goals: a literature review. *Glob Public Health.* 2013; 8:1109–22. [PubMed: 24266508]
17. Stuckler D, Basu S, McKee M. Drivers of inequality in Millennium Development Goal progress: a statistical analysis. *PLoS Med.* 2010; 7:e1000241. [PubMed: 20209000]
18. Vitoria M, Granich R, Gilks CF, et al. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. *Am J Clin Pathol.* 2009; 131:844–48. [PubMed: 19461091]
19. Alleyne G, Binagwaho A, Haines A, et al. Lancet NCD Action Group. Embedding non-communicable diseases in the post-2015 development agenda. *Lancet.* 2013; 381:566–74. [PubMed: 23410606]
20. MEDICC. NCDs: can healthy synergies replace fatal interactions? *MEDICC Rev.* 2013; 15:3.
21. WHO. WEF. From Burden to 'Best Buys': Reducing the Economic Impact of Non-Communicable Diseases in Low- and Middle-Income Countries. World Economic Forum; 2011. http://www3.weforum.org/docs/WEF_WHO_HE_ReducingNonCommunicableDiseases_2011.pdf [accessed February 26, 2014]
22. WEF. Harvard School of Public Health. Glob. Econ. Burd. Non-Commun. Dis. World Econ. Forum; The Global Economic Burden of Non-communicable Diseases. <http://www.weforum.org/reports/global-economic-burden-non-communicable-diseases> [accessed February 27, 2014]
23. [accessed February 27, 2014] 2011 High Level Meeting on the Prevention and Control of Non-communicable Diseases. <https://www.un.org/en/ga/ncdmeeting2011/>
24. Alliance NCD. Tackling Non-communicable Diseases to Enhance Sustainable Development. NCD Alliance; 2014. http://ncdalliance.org/sites/default/files/NCD%20Alliance%20-%20NCDs%20and%20Sustainable%20Development%20Brief_0.pdf [accessed February 26, 2014]
25. Beaglehole R, Bonita R, Horton R, et al. Lancet NCD Action Group; NCD Alliance. Priority actions for the non-communicable disease crisis. *Lancet.* 2011; 377:1438–47. [PubMed: 21474174]
26. Abegunde DO, Mathers CD, Adam T, Ortegón M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet.* 2007; 370:1929–38. [PubMed: 18063029]

Lancet. Author manuscript; available in PMC 2014 October 20.

27. Shiffman J. Has donor prioritization of HIV/AIDS displaced aid for other health issues? *Health Policy Plan.* 2008; 23:95–100. [PubMed: 18156161]
28. Vandemoortele J, Delamonica E. Taking the MDGs Beyond 2015: Hasten Slowly. *IDS Bull.* 2010; 41:60–69.
29. UNAIDS. 2011–2015 Strategy: Getting to Zero. Joint United Nations Programme on HIV/AIDS; 2010. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/JC2034_UNAIDS_Strategy_en.pdf
30. Treatment Action Group. [accessed March 5, 2014] The Zero Declaration. 2012. <http://www.treatmentactiongroup.org/tb/advocacy/zero-declaration>
31. Department for International Development. UKAID. Towards zero infections: The UK's position paper on HIV in the developing world. 2011. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/67523/twds-zero-infs-pos-paper-hiv-dev-wrld.pdf
32. South Africa Info Reporter. South Africa's HIV/Aids battle plan. 2012. <http://www.southafrica.info/about/health/aids-prevention.htm#.UxZ1nflDXg9>
33. WHO. Roadmap for Childhood Tuberculosis. 2013. http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137_eng.pdf
34. Stop, TB. Towards Zero TB Deaths In Children. WHO; 2012. Partnership. No More Crying, No More Dying. http://www.stoptb.org/assets/documents/news/ChildhoodTB_report_singles.pdf
35. Ki-moon, B. [accessed March 5, 2014] Secretary-General's message on World Malaria Day. 2011. [un.orghttp://www.un.org/sg/statements/?nid=5219](http://www.un.org/sg/statements/?nid=5219)
36. Wagstaff, A. The Millennium Development Goals for Health: Rising to the Challenges. World Bank Publications; 2004.
37. UNAIDS. AIDSinfo Database. Joint United Nations Programme on HIV/AIDS; 2013. <http://www.aidsinfoonline.org/devinfo/libraries/asp/Home.aspx>
38. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. *Sex Transm Infect.* 2012; 88(suppl 2):i11–16. [PubMed: 23172341]
39. UNAIDS. Methodology – Understanding the HIV estimates. Geneva, Switzerland: 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/20131118_Methodology.pdf
40. Pretorius C, Menzies NA, Chindelevitch L, et al. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models. *AIDS.* 2014; 28(suppl 1):S25–34. [PubMed: 24468944]
41. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. *Lancet.* 2012; 380:2055–58. [PubMed: 23245598]
42. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. *Lancet.* 2012; 380:2063–66. [PubMed: 23245602]
43. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380:2071–94. [PubMed: 23245603]
44. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380:2129–43. [PubMed: 23245605]
45. Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. *Lancet.* 2012; 380:2144–62. [PubMed: 23245606]
46. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380:2163–96. [PubMed: 23245607]
47. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380:2197–223. [PubMed: 23245608]
48. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic

Lancet. Author manuscript; available in PMC 2014 October 20.

- analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012; 380:2224–60. [PubMed: 23245609]
49. The GBD 2013 Collaboration. Global, Regional, and National Burden of Disease for 322 Disease and Injuries and 68 Risk Factors, 1990-2013: A Systematic Analysis. In preparation.
 50. The GBD 2013 Collaboration. Global, Regional, and National Levels of Age-Specific Mortality and 266 Causes of Death, 1990-2013: A Systematic Analysis. In preparation.
 51. The GBD 2013 Collaboration. Global, Regional, and National Prevalence and Disability for 318 Disease and Injuries and Their 2,435 Sequelae, 1990-2013: A Systematic Analysis. In preparation.
 52. Ghys PD, Brown T, Grassly NC, et al. The UNAIDS Estimation and Projection Package: a software package to estimate and project national HIV epidemics. *Sex Transm Infect*. 2004; 80(suppl 1):i5–9. [PubMed: 15249692]
 53. Brown T, Grassly NC, Garnett G, Stanecki K. Improving projections at the country level: the UNAIDS Estimation and Projection Package 2005. *Sex Transm Infect*. 2006; 82(suppl 3):iii34–40. [PubMed: 16735291]
 54. Todd J, Glynn JR, Marston M, et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. *AIDS*. 2007; 21(suppl 6):S55–63. [PubMed: 18032940]
 55. Ghys PD, Zaba B, Prins M. Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. *AIDS*. 2007; 21(suppl 6):S1–4. [PubMed: 18032932]
 56. Hallett TB, Zaba B, Todd J, et al. ALPHA Network. Estimating incidence from prevalence in generalised HIV epidemics: methods and validation. *PLoS Med*. 2008; 5:e80. [PubMed: 18590346]
 57. McGowan CC, Cahn P, Gotuzzo E, et al. Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. *Int J Epidemiol*. 2007; 36:969–76. [PubMed: 17846055]
 58. Nash D, Katyal M, Brinkhof MWG, et al. ART-LINC Collaboration of IeDEA. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. *AIDS*. 2008; 22:2291–302. [PubMed: 18981768]
 59. Verguet S, Lim SS, Murray CJL, Gakidou E, Salomon JA. Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs. *J Infect Dis*. 2013; 207:72–79. [PubMed: 23100567]
 60. UNAIDS. Global Report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS; 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf [accessed 26 Feb 2014]
 61. WHO. Case Study on Estimating HIV Infection in a Concentrated Epidemic: Lessons from Indonesia. WHO; 2004. <http://www.who.int/hiv/pub/epidemiology/indonesia/en/> [accessed February 27, 2014]
 62. Papworth E, Ceesay N, An L, et al. Epidemiology of HIV among female sex workers, their clients, men who have sex with men and people who inject drugs in West and Central Africa. *J Int AIDS Soc*. 2013; 16(suppl 3):18751. [PubMed: 24321113]
 63. Bautista-Arredondo S, Colchero MA, Romero M, Conde-Glez CJ, Sosa-Rubí SG. Is the HIV epidemic stable among MSM in Mexico? HIV prevalence and risk behavior results from a nationally representative survey among men who have sex with men. *PLoS ONE*. 2013; 8:e72616. [PubMed: 24039786]
 64. Ruan Y, Liang S, Zhu J, et al. Gender and ethnic disparities of HIV and syphilis seroconversions in a 4-year cohort of injection drug users. *Southeast Asian J Trop Med Public Health*. 2013; 44:842–53. [PubMed: 24437319]
 65. Decker MR, Wirtz AL, Moguilnyi V, et al. Female Sex Workers in Three Cities in Russia: HIV Prevalence, Risk Factors and Experience with Targeted HIV Prevention. *AIDS Behav*. 2014; 18:562–72. [PubMed: 23929034]

66. Miller WM, Buckingham L, Sánchez-Domínguez MS, Morales-Miranda S, Paz-Bailey G. Systematic review of HIV prevalence studies among key populations in Latin America and the Caribbean. *Salud Publica Mex.* 2013; 55(suppl 1):S65–78. [PubMed: 23918059]
67. Mason K, Ketende S, Peitzmeier S, et al. A cross-sectional analysis of population demographics, HIV knowledge and risk behaviors, and prevalence and associations of HIV among men who have sex with men in the Gambia. *AIDS Res Hum Retroviruses.* 2013; 29:1547–52. [PubMed: 23875674]
68. Li D, Wang L, Lin W, et al. HIV and syphilis infections among street-based female sex workers in China, 2010–2012. *Chin Med J (Engl).* 2014; 127:707–11. [PubMed: 24534227]
69. Sajadi L, Mirzazadeh A, Navadeh S, et al. HIV prevalence and related risk behaviours among female sex workers in Iran: results of the national biobehavioural survey, 2010. *Sex Transm Infect.* 2013; 89(suppl 3):iii37–40. [PubMed: 24191292]
70. Mathers BM, Degenhardt L, Ali H, et al. 2009 Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet.* 2010; 375:1014–28. [PubMed: 20189638]
71. Mathers BM, Degenhardt L, Phillips B, et al. 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet.* 2008; 372:1733–45. [PubMed: 18817968]
72. Prüss-Ustün A, Wolf J, Driscoll T, Degenhardt L, Neira M, Calleja JMG. HIV due to female sex work: regional and global estimates. *PLoS ONE.* 2013; 8:e63476. [PubMed: 23717432]
73. UNAIDS. WHO. Guidelines for measuring national HIV prevalence in population-based surveys. Joint United Nations Programme on HIV/AIDS; Geneva: 2005. http://data.unaids.org/pub/manual/2005/20050101_gs_guidemeasuringpopulation_en.pdf
74. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380:2095–128. [PubMed: 23245604]
75. Birnbaum JK, Murray CJ, Lozano R. Exposing misclassified HIV/AIDS deaths in South Africa. *Bull World Health Organ.* 2011; 89:278–85. [PubMed: 21479092]
76. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr.* 2012; 10:1. [PubMed: 22226226]
77. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. *JAMA.* 2014; 311:183–92. [PubMed: 24399557]
78. USAID. Demographic Health Surveys Program. <http://www.dhsprogram.com/>
79. International Institute for Population Sciences. National Family Health Survey, India. Mumbai, India: <http://www.rchiips.org/nfhs/>
80. Simbayi, L.; Shisana, O.; Rehle, T.; et al. Human Sciences Resource Council. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. 2014. <http://www.hsrb.ac.za/en/research-outputs/view/6871>
81. Dye C, Lönnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. *Bull World Health Organ.* 2009; 87:683–91. [PubMed: 19784448]
82. WHO. Global tuberculosis report 2013. 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
83. WHO. Tuberculosis prevalence surveys: a handbook. WHO; 2011. http://www.who.int/tb/advisory_bodies/impact_measurement_taskforce/resources_documents/thelimebook/en/ [accessed February 26, 2014]
84. WHO. Global Task Force on TB Impact Measurement. National TB prevalence surveys; 2014.
85. Naghavi M, Makela S, Foreman K, O'Brien J, Pourmalek F, Lozano R. Algorithms for enhancing public health utility of national causes-of-death data. *Popul Health Metr.* 2010; 8:9. [PubMed: 20459720]
86. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. *J Infect Dis.* 2005; 191:150–58. [PubMed: 15609223]

Lancet. Author manuscript; available in PMC 2014 October 20.

87. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. *Am Rev Respir Dis.* 1992; 146:1439–44. [PubMed: 1456559]
88. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. *Am Rev Respir Dis.* 1991; 143:501–04. [PubMed: 2001057]
89. Keizer ST, Langendam MM, van Deutekom H, Coutinho RA, van Ameijden EJC. How does tuberculosis relate to HIV positive and HIV negative drug users? *J Epidemiol Community Health.* 2000; 54:64–68. [PubMed: 10692965]
90. Leroy V, Msellati P, Lepage P, et al. Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1995; 9:415–21. [PubMed: 7600110]
91. Houben RMGJ, Glynn JR, Mboma S, et al. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. *AIDS.* 2012; 26:2233–39. [PubMed: 22951633]
92. Ferreira MM, Ferrazoli L, Palaci M, et al. Tuberculosis and HIV infection among female inmates in São Paulo, Brazil: a prospective cohort study. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1996; 13:177–83. [PubMed: 8862283]
93. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet.* 2002; 359:2059–64. [PubMed: 12086758]
94. Murray CJL, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. *Lancet.* 2012; 379:413–31. [PubMed: 22305225]
95. Byass P, de Courten M, Graham WJ, et al. Reflections on the global burden of disease 2010 estimates. *PLoS Med.* 2013; 10:e1001477. [PubMed: 23843748]
96. Lynch M, Korenromp E, Eisele T, et al. New global estimates of malaria deaths. *Lancet.* 2012; 380:559. [PubMed: 22883496]
97. Bates M, O'Grady J, Mudenda V, Shibemba A, Zumla A. New global estimates of malaria deaths. *Lancet.* 2012; 380:560–61. [PubMed: 22883498]
98. Chambers RG. UN Envoy's response to estimates of global malaria mortality. *Lancet.* 2012; 379:707–08. [PubMed: 22357104]
99. Shah NK, Kumar A, Valecha N. New global estimates of malaria deaths. *Lancet.* 2012; 380:560. [PubMed: 22883499]
100. White NJ, Dondorp AM, Faiz A, Mishra S, Hien TT. New global estimates of malaria deaths. *Lancet.* 2012; 380:559–60. [PubMed: 22883497]
101. Snow RW, Armstrong JR, Forster D, et al. Childhood deaths in Africa: uses and limitations of verbal autopsies. *Lancet.* 1992; 340:351–55. [PubMed: 1353814]
102. Mpimbaza A, Filler S, Katureebe A, et al. Validity of verbal autopsy procedures for determining malaria deaths in different epidemiological settings in Uganda. *PLoS ONE.* 2011; 6:e26892. [PubMed: 22046397]
103. Nykanen M, Tamaona W, Cullinan T, Van Oosterzee V, Ashorn P. Verbal autopsy as a technique to establish causes of infant and child mortality. *East Afr Med J.* 1995; 72:731–34. [PubMed: 8904066]
104. Todd JE, De Francisco A, O'Dempsey TJ, Greenwood BM. The limitations of verbal autopsy in a malaria-endemic region. *Ann Trop Paediatr.* 1994; 14:31–36. [PubMed: 7516132]
105. Setel PW, Whiting DR, Hemed Y, et al. Validity of verbal autopsy procedures for determining cause of death in Tanzania. *Trop Med Int Health.* 2006; 11:681–96. [PubMed: 16640621]
106. Chandramohan D, Maude GH, Rodrigues LC, Hayes RJ. Verbal autopsies for adult deaths: their development and validation in a multicentre study. *Trop Med Int Health.* 1998; 3:436–46. [PubMed: 9657505]
107. Murray CJL, Lozano R, Flaxman AD, et al. Using verbal autopsy to measure causes of death: the comparative performance of existing methods. *BMC Med.* 2014; 12:5. [PubMed: 24405531]
108. Gething PW, Patil AP, Smith DL, et al. A new world malaria map: *Plasmodium falciparum* endemicity in 2010. *Malar J.* 2011; 10:378. [PubMed: 22185615]

109. Dieleman JL, Graves CM, Templin T, et al. Global health development assistance remained steady in 2013 but did not align with recipients' disease burden. *Health Aff (Millwood)*. 2014; 33:878–86. [PubMed: 24714869]
110. WHO. [accessed 10 Mar 2014] World Malaria Report. 2013. 2013. http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/
111. Yang X, Jiao YM, Wang R, et al. High CCR5 density on central memory CD4+ T cells in acute HIV-1 infection is mostly associated with rapid disease progression. *PLoS ONE*. 2012; 7:e49526. [PubMed: 23185351]
112. International HIV Controllers Study. Pereyra F, Jia X, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*. 2010; 330:1551–57. [PubMed: 21051598]
113. Herbeck JT, Gottlieb GS, Winkler CA, et al. Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. *J Infect Dis*. 2010; 201:618–26. [PubMed: 20064070]
114. Freguja R, Giancesin K, Del Bianco P, et al. Polymorphisms of innate immunity genes influence disease progression in HIV-1-infected children. *AIDS*. 2012; 26:765–68. [PubMed: 22269973]
115. Freguja R, Giancesin K, Zanchetta M, De Rossi A. Cross-talk between virus and host innate immunity in pediatric HIV-1 infection and disease progression. *New Microbiol*. 2012; 35:249–57. [PubMed: 22842595]
116. Hewitt K, Steketee R, Mwapasa V, Whitworth J, French N. Interactions between HIV and malaria in non-pregnant adults: evidence and implications. *AIDS*. 2006; 20:1993–2004. [PubMed: 17053345]
117. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. *Lancet Infect Dis*. 2011; 11:541–56. [PubMed: 21700241]
118. Umunyana, J. [accessed 11 Apr 2014] Incidence of Malaria in HIV-infected and uninfected and Rwandan women from 2005 to 2011. 2014. <http://wiredspace.wits.ac.za/handle/10539/14502>
119. UNAIDS. 2007 AIDS Epidemic Update. 2007. http://data.unaids.org/pub/epislides/2007/2007_epiupdate_en.pdf
120. Donnell D, Baeten JM, Kiarie J, et al. Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet*. 2010; 375:2092–98. [PubMed: 20537376]
121. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS*. 2009; 23:1397–404. [PubMed: 19381076]
122. Jackson DJ, Chopra M, Doherty TM, et al. Good Start Study Group. Operational effectiveness and 36 week HIV-free survival in the South African programme to prevent mother-to-child transmission of HIV-1. *AIDS*. 2007; 21:509–16. [PubMed: 17301570]
123. Dabis F, Bequet L, Ekouevi DK, et al. ANRS 1201/1202 DITRAME PLUS Study Group. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. *AIDS*. 2005; 19:309–18. [PubMed: 15718842]
124. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. *Lancet*. 2004; 364:1428–34. [PubMed: 15488218]
125. Chintu C, Bhat GJ, Walker AS, et al. CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. *Lancet*. 2004; 364:1865–71. [PubMed: 15555666]
126. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. *N Engl J Med*. 2001; 344:824–31. [PubMed: 11248160]
127. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings—the case of Côte d'Ivoire. *N Engl J Med*. 2006; 355:1141–53. [PubMed: 16971720]
128. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa—a primary data analysis. *Cost Eff Resour Alloc*. 2006; 4:20. [PubMed: 17147833]

129. Degenhardt L, Mathers BM, Wirtz AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. *Int J Drug Policy*. 2014; 25:53–60. [PubMed: 24113623]
130. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. *Pulm Med*. 2013; 2013:828939. DOI:10.1155/2013/828939. [PubMed: 23476764]
131. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. *Arch Intern Med*. 2007; 167:335–42. [PubMed: 17325294]
132. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. *Soc Sci Med*. 2009; 68:2240–46. [PubMed: 19394122]
133. Espinal MA. The global situation of MDR-TB. *Tuberculosis (Edinb)*. 2003; 83:44–51. [PubMed: 12758188]
134. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. *J Infect Dis*. 2006; 194:479–85. [PubMed: 16845631]
135. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. *N Engl J Med*. 2012; 366:2161–70. [PubMed: 22670902]
136. WHO. Global tuberculosis control 2010. http://www.who.int/tb/publications/global_report/2010/en/
137. Mehra M, Cossrow N, Kambili C, Underwood R, Makkar R, Potluri R. Assessment of tuberculosis burden in China using a dynamic disease simulation model. *Int J Tuberc Lung Dis*. 2013; 17:1186–94. [PubMed: 23827732]
138. Malaria Funding & Resource Utilization: The First Decade of Roll Back Malaria. 2010. Roll Back Malaria.
139. Otten M, Aregawi M, Were W, et al. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment. *Malar J*. 2009; 8:14. [PubMed: 19144183]
140. Steketee RW, Campbell CC. Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. *Malar J*. 2010; 9:299. [PubMed: 20979634]
141. O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. *Lancet Infect Dis*. 2010; 10:545–55. [PubMed: 20637696]
142. Noor AM, Kinyoki DK, Mundia CW, et al. The changing risk of *Plasmodium falciparum* malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. *Lancet*. 2014 DOI:10.1016/S0140-6736(13)62566-0.
143. WHO. Q & A on malaria mortality estimates. 2012. http://www.searo.who.int/entity/malaria/WHOGMP_burden_estimates_qa.pdf
144. Shah NK. Defining & counting malaria deaths. *Indian J Med Res*. 2012; 135:270–72. [PubMed: 22561610]
145. Shah NK, Dhariwal AC, Sonal GS, Gunasekar A, Dye C, Cibulskis R. Malaria-attributed death rates in India. *Lancet*. 2011; 377:991. author reply 994-95. [PubMed: 21420545]
146. Crump JA, Morrissey AB, Nicholson WL, et al. Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study. *PLoS Negl Trop Dis*. 2013; 7:e2324. [PubMed: 23875053]
147. Reyburn H, Mbatia R, Drakeley C, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. *BMJ*. 2004; 329:1212. [PubMed: 15542534]
148. Nadjm B, Mtove G, Amos B, et al. Severe febrile illness in adult hospital admissions in Tanzania: a prospective study in an area of high malaria transmission. *Trans R Soc Trop Med Hyg*. 2012; 106:688–95. [PubMed: 23022040]
149. Makani J, Matuja W, Liyombo E, Snow RW, Marsh K, Warrell DA. Admission diagnosis of cerebral malaria in adults in an endemic area of Tanzania: implications and clinical description. *QJM*. 2003; 96:355–62. [PubMed: 12702784]
150. Snow RW, Korenromp EL, Gouws E. Pediatric mortality in Africa: *Plasmodium falciparum* malaria as a cause or risk? *Am J Trop Med Hyg*. 2004; 71(suppl):16–24. [PubMed: 15331815]

Lancet. Author manuscript; available in PMC 2014 October 20.

151. Scott JAG, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. *Lancet*. 2011; 378:1316–23. [PubMed: 21903251]
152. Shanks GD, Hay SI, Bradley DJ. Malaria's indirect contribution to all-cause mortality in the Andaman Islands during the colonial era. *Lancet Infect Dis*. 2008; 8:564–70. [PubMed: 18599354]
153. Gray RH. The decline of mortality in Ceylon and the demographic effects of malaria control. *Popul Stud (Camb)*. 1974; 28:205–29. [PubMed: 11630544]
154. Giglioli G. Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community. *Bull World Health Organ*. 1972; 46:181–202. [PubMed: 4624339]
155. D'Alessandro U, Olaleye BO, McGuire W, et al. Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme. *Lancet*. 1995; 345:479–83. [PubMed: 7861874]
156. Alonso PL, Lindsay SW, Armstrong JR, et al. The effect of insecticide-treated bed nets on mortality of Gambian children. *Lancet*. 1991; 337:1499–502. [PubMed: 1675368]
157. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, UK Haemophilia Centre Directors' Organisation. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. *Lancet*. 1996; 347:1573–79. [PubMed: 8667864]
158. Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. *Lancet*. 2008; 372:1545–54. [PubMed: 18984187]
159. Ceesay SJ, Casals-Pascual C, Nwakanma DC, et al. Continued decline of malaria in The Gambia with implications for elimination. *PLoS ONE*. 2010; 5:e12242. [PubMed: 20805878]
160. Futures Institute. [accessed Feb 26, 2014] AIM: a computer program for making HIV/AIDS projections and examining the demographic and social impacts of AIDS. <https://spectrummodel.zendesk.com/attachments/token/6eixzeawlonxjg7/?name=AIM+2014+English.pdf>
161. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet*. 2012; 379:2151–61. [PubMed: 22579125]
162. WHO. [accessed Jun 12, 2014] World Malaria Report 2008. <http://www.who.int/malaria/publications/atoz/9789241563697/en/>
163. Hay SI, Okiro EA, Gething PW, et al. Estimating the Global Clinical Burden of *Plasmodium falciparum* Malaria in 2007. *PLoS Med*. 2010; 7:e1000290. [PubMed: 20563310]
164. Snow, RW.; Newton, CRJC. The public health burden of *Plasmodium falciparum* malaria in Africa: deriving the numbers. The Disease Control Priorities Project (DCPP); Washington DC: 2003. p. 75 Working Paper Number 11